This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.
Study Type
OBSERVATIONAL
Enrollment
150
Baseline Demographics
Time frame: Baseline (Month 1)
Change From Baseline in Patient-Reported Outcomes Scores
Time frame: Baseline up to Month 61
Change From Baseline in Serum KIT D816V Variant Allele Frequency (VAF)
Time frame: Baseline up to Month 61
Change From Baseline in Serum Tryptase
Time frame: Baseline up to Month 61
Change From Baseline in Indolent Systemic Mastocytosis (ISM) Symptom-Directed Therapies
Time frame: Baseline up to Month 61
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.